Is there transparency in the pricing of medicines in the South African private sector? by Bangalee, V & Suleman, F
82       February 2018, Vol. 108, No. 2
IN PRACTICE
Recent investigations by the Competition Commission of South 
Africa (SA) of suspected excessive pricing of cancer medicines 
in South Africa (SA) by three global pharmaceutical companies, 
i.e. Roche Holding AG (Roche), Pfizer Inc. (Pfizer) and Aspen 
Pharmacare Holdings Ltd (Aspen), have once again drawn attention 
to the need for medicine pricing transparency. These companies have 
been accused of engaging in excessive pricing, price discrimination 
and/or exclusionary conduct in the provision of breast cancer 
medicine in SA.[1] 
Previously, in the SA private sector, medicine price inflation, medicine 
price transparency and medicine price uniformity represented significant 
problems in an unregulated medicines market.[2] The loss of benefits to 
consumers resulting from the high levels of discounting and payment 
of incentives within the pharmaceuticals supply chain had raised 
serious concerns in the National Department of Health and made it 
difficult to determine the true price of a medicine.[3] The single exit 
price (SEP) regulation, first introduced in 2004 for all medicines in 
the private sector, is an example of SA’s attempt to control prices and 
improve pricing transparency in the supply chain. The SEP, which is a 
composite of the ex-manufacturer’s price, logistics fee and value added 
tax (VAT), standardised in SA at 14%, mandated that manufacturers sell 
their products at one price to all their customers (other than the State), 
regardless of the nature of the customer’s order size and consumption 
levels.[4,5] Under this regulation, manufacturers were allowed to set their 
SEP at the time of introduction of the product, which may be raised once 
on an annual basis. They may, however, make several temporary price 
reductions during the year for competitive reasons.[6] 
However, over a decade since its introduction as a price-control 
measure for medicines, complaints about access to affordable medi-
cines in SA still persist. After the initial cost reduction brought about 
by the SEP, there has not been any formal adjudication of prices 
against comparable products in SA. Prices remain artificially inflated 
compared with the same products available internationally,[7] as is the 
premise for the case against Pfizer, which is being investigated for 
excessive pricing of the lung cancer medication Xalkori (crizotinib) 
in SA.[1] Similarly, Aspen, which is the dominant firm in the provision 
of Leukeran (chlorambucil), Alkeran (melphalan) and Myleran 
(busulfan) in SA, has seemingly taken advantage of their monopoly in 
the market and are under investigation for excessive pricing of these 
medicines.[1] After observing that medicine prices and out-of-pocket 
spending on medicines were increasing, consumer advocates and 
policy makers have called for greater price transparency.[8] Several 
factors have been recognised that constitute reduced transparency in 
the supply chain.
Among these is a lack of transparency in determining the logistics 
fee segment of the SEP. The logistics fee is determined through 
negotiations between the manufacturer or importer and the logistics 
service provider; however, the process and contracts are not made 
public. Manufacturers pay wholesalers and distributors a logistics fee 
from the SEP, but it is not evident if all logistics service providers are 
able to negotiate the same fee or if the fee is as reflected in the medicines 
database (South African Medicine Price Registry).[9] The nature of these 
negotiations, which include concealment by manufacturers of prices 
or a price-setting approach, represents a barrier to price transparency 
in the SEP.[10] The allegation by stakeholders, such as Transpharm, 
that the logistics fee is being exploited by pharmaceutical companies, 
led to the following proposals.[11] Firstly, transparency in the logistics 
fee is required by Regulation 21(2)(d) of the Medicines and Related 
Substances Act, 1965 (Act No. 101 of 1965), as amended. Secondly, 
Regulation 5(2)(f) states that the manufacturer and logistics provider 
must agree on a fee; and, thirdly, that under Regulation 5(2)(g) there 
be a cap on the logistics fee (as opposed to a fixed fee).[11]
In addition to the logistics fee, SA’s current patent laws further 
contribute to artificially inflated prices. As argued by some parties, 
pharmaceutical manufacturers have a broad discretion in deter-
mining the prices they charge, and patent protection provides a 
source of monopoly that allows manufacturers a higher profit than 
the marginal cost of production.[7] ‘Ever-greening’ of products also 
remains a significant issue, as manufacturers prolong their patents 
through marginal adaptations to product formulations. In most 
instances, these adaptations do not offer any clinically significant 
advantages to patients – the more pertinent consequence being the 
barrier to generic medicine entry for many years beyond the original 
patent. This limits medicine accessibility and artificially sustains the 
inflated cost of a medicine.[7] Roche has been suspected of using the 
ever-greening strategy for its breast cancer medicines (Herceptin 
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(trastuzumab) and Herclon (trastuzumab)) to the detriment of 
patients and in contravention of the Competition Act.[1]
Under the current SEP regulation, companies of originator medi-
cines still have the freedom to set launch prices. However, the Pricing 
Committee is responsible for determining annual price increases in 
accordance with the SEP regulation methodology. Consequently, 
pricing of these medicines remains largely at the discretion of 
the manufacturer. In this regard, government has proposed the 
introduction of an international benchmarking system, in which 
the prices of originator medicines will be compared with those in 
a basket of countries (Australia, Canada, New Zealand and Spain, 
together with SA). For generic medicines, the ex-manufacturer price 
is to be set at least 40% lower than the existing price of the originator 
medicine.[12] The process is likely to reduce the SEP of medicines in 
SA and create some transparency of pricing at the ex-manufacturer 
level. This legislative framework has been in the pipeline since 2006, 
but has faced stiff lobbies in terms of implementation. If implemented, 
it would reduce originator medicine costs by ~25%.[13] In addition to 
international benchmarking, the application of pharmacoeconomics 
analyses on a voluntary basis has also been proposed to determine 
medicine prices. This provision, however, requires considerable 
resources and capacity on the part of the manufacturers to prepare 
submissions, as well as by the Pricing Committee to critically assess 
the submissions and make defensible determinations on that basis.[9] 
Arguments against increased transparency of negotiations and 
publication of detailed individualised pricing data derive mainly 
from manufacturers, as it carries the risk of allowing competitors 
to be aware of other manufacturers’ pricing strategies and therefore 
exposes companies to antitrust liability. Antitrust laws prohibit 
activities that restrict competition. This exchange of commercially 
sensitive information between competitors may facilitate price 
co-ordination and result in standardisation of prices. Thus, any 
system aimed at increasing price transparency should always be 
cautionary of antitrust rules and try to simultaneously establish a fair 
price for medicines.[14]
It is also vital that there is greater transparency and consistency in 
the pricing of medicines across the SA public and private healthcare 
sectors. The economic objectives of the National Drug Policy have 
been to attain affordable prices for all SA citizens, but there are 
irregularities and discrepancies in medicine pricing across the two 
sectors. Price variations exist because public, private and non-
governmental sectors procure medicines separately. Comparative 
state tender prices have revealed that some medicines are available 
to the state at approximately one-tenth of the cost of the same 
medicine in the private sector.[7] Roche has been implicated in price 
discrimination by charging differential prices for breast cancer 
medicines in the private and public healthcare sectors by restricting 
the sale of Herceptin and Herclon to a particular sector.[1] It has been 
estimated that a 12-month course of Herceptin costs ≥R500 000  in 
the private sector, whereas Roche offers substantially lower prices for 
Herclon in the public sector.[1] The need for more consistent prices 
becomes imperative in lieu of the move to introduce universal health 
coverage in SA. 
Finally, it has been suggested that transparency in the pricing 
of medicines would empower patients to make more informed 
choices, understand how prices are set and become aware of price 
discrimination.[10] According to standard economic theory, in most 
markets, price transparency leads to lower and more uniform prices. 
Unfortunately, there has been little research conducted to determine 
if this premise also holds true for the pharmaceutical market.
Conclusion
SA’s medicine pricing interventions are synonymous with an 
acrimonious history of implementation. Despite government’s success 
in implementing several key polices to reduce medicine prices, 
considerable more research is required to ascertain if implemented 
policies have produced the appropriate positive outcomes. Much 
of the published literature on SA’s policy development has covered 
aspects of the history and a general overview; however, there is a 
dearth of studies that have looked at policy impact and implication. 
These studies have become more important as SA moves towards 
universal healthcare coverage, as this transformation requires inte-
grating the strongest facets of all policies to ensure sustainable access 
to quality, affordable essential medicines. Transparency in pricing 
needs to be achieved as well, but to policy makers alone or also to 
the general public? Does the business model need to be changed for 
pharmaceuticals? These are questions that the European Union, the 
USA and even the World Health Organization are currently grapp-
ling with.
Acknowledgements. None.
Author contributions. VB and FS both contributed to the article.
Funding. Research reported in this publication was supported by the 
Fogarty International Center (FIC), National Institutes of Health  (NIH) 
Common Fund, Office of Strategic Coordination, Office of the Director 
(CF/OSC/OD/NIH), Office of AIDS Research, Office of the Director 
(OAR/OD/NIH), National Institute of Mental Health (NIMH/NIH), 
award number D43TW010131. The content is solely the responsibility of 
the authors and does not necessarily represent the official views of the 
NIH.
Conflicts of interest. None. 
1. Business Report. #BadPharma: Pharmaceutical companies behind high cost for cancer medication. 
2017. https://www.iol.co.za/business-report/badpharma-pharmaceutical-companies-behind-high-
cost-for-cancer-medication-9770177 (accessed 11 December 2017). 
2. Carapinha and Company. Single exit price legislation: A source of harm to competition. 2016. 
http://www.carapinha.com/single-exit-price-legislation-a-source-of-harm-to-competition/#sthash.
nXKTewtG.dpuf (accessed 11 December 2017).
3. Bangalee V, Suleman F. Has the increase in the availability of generic drugs lowered the price 
of cardiovascular drugs in South Africa? Health SA 2016;21:60-66. https://doi.org/10.1016/j.
hsag.2015.10.004
4. Bodhania M. Pharmaceutical sector presentation for private health sector Indaba. 2007. http://
www.slideserve.com/moeshe/pharmaceutical-sector-presentation-for-private-health-sector-indaba 
(accessed 11 December 2017).
5. Nicolosi E, Gray A. Potential cost savings from generic medicines – protecting the prescribed 
minimum benefits. S Afr Fam Pract 2009;51(1):59-63.
6. Ngozwana S. Policies to control prices of medicines: Does the South African experience have lessons 
for other African countries? In: Banda G, Tibandebage P, Wamae W, eds. Making Medicines in Africa. 
Hampshire, UK: Palgrave Macmillan, 2016:203-223.
7. Makholwa A. Medicine pricing: New prescriptions needed. 2014. http://ftp.bhfglobal.com/new-
prescriptions-needed (accessed 14 December 2017).
8. Hawkins L. Review Series on Pharmaceutical Pricing Policies and Interventions: Working Paper 4: 
Competition Policy. World Health Organization/Health Action International Project on Medicine 
Prices and Availability. Geneva: WHO/HAI, 2011.
9. Gray A, Suleman F. Pharmaceutical pricing in South Africa. In: Babar Z, ed. Pharmaceutical Prices in 
the 21st Century. Switzerland: Springer, 2015:251-265.
10. Austin DA, Gravelle JG. Does price transparency improve market efficiency? Implications of empirical 
evidence in other markets for the health sector. 2007. https://www.fas.org/sgp/crs/misc/RL34101.pdf 
(accessed 11 December 2017).
11. Board of Healthcare Funders of Southern Africa. Health sector inquiry: Pharmaceutical task group’s 
response to third party submissions concerning the pharmaceutical sector. http://www.compcom.
co.za/wp-content/uploads/2015/05/PTG-Submission-Response-to-Stakeholders1.pdf (accessed 
11 December 2017).
12. Taylor B. Rationing of medicines and health care technology: Pooling of resources and purchasing of 
health care. S Afr Health Rev 2007;1:123-137.
13. Van den Heever A. Review of competition in the South African health system. 2012. http://www.
compcom.co.za/wp-content/uploads/2014/09/Review-of-Competition-in-the-South-African-Health-
System.pdf (accessed 11 December 2017).
14. Daems R, Maes E. Global pharmaceutical management: Building a fair pricing policy (No. 2014/05). 
2014. http://web2.msm.nl/RePEc/msm/wpaper/MSM-WP2014-05.pdf (accessed 3 January 2018).
Accepted 18 September 2017.
